|Articles|March 23, 2021
GxP regulated industry assessments of SoftMax Pro Software
Author(s)Molecular Devices
This document outlines references to 21 CFR Part 11 and EudraLex Annex 11 and how they apply to the implementation of SoftMax Pro GxP Data Acquisition and Analysis Software in regulated environments.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Top 10 BioPharm International Articles of 2025
2
Year in Review: How FDA Guidances Defined the 2025 Biopharma Landscape
3
Building Robust Biomanufacturing Networks for the Next Wave of Therapies
4
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
5